المؤلفون: Chen, Linda L., Lauwers, Iris, Verduijn, Gerda, Philippens, Marielle, Gahrmann, Renske, Capala, Marta E., Petit, Steven

المساهمون: Klinische Fysica RT, Cancer

مصطلحات موضوعية: apparent diffusion coefficient, head and neck carcinoma, human papillomavirus, magnetic resonance imaging, oropharyngeal squamous cell carcinoma, systematic review, Oncology, Cancer Research

الوصف: Human papillomavirus (HPV) is an important risk factor for oropharyngeal squamous cell carcinoma (OPSCC). HPV-positive (HPV+) cases are associated with a different pathophysiology, microstructure, and prognosis compared to HPV-negative (HPV−) cases. This review aimed to investigate the potential of magnetic resonance imaging (MRI) to discriminate between HPV+ and HPV− tumours and predict HPV status in OPSCC patients. A systematic literature search was performed on 15 December 2022 on EMBASE, MEDLINE ALL, Web of Science, and Cochrane according to PRISMA guidelines. Twenty-eight studies (n = 2634 patients) were included. Five, nineteen, and seven studies investigated structural MRI (e.g., T1, T2-weighted), diffusion-weighted MRI, and other sequences, respectively. Three out of four studies found that HPV+ tumours were significantly smaller in size, and their lymph node metastases were more cystic in structure than HPV− ones. Eleven out of thirteen studies found that the mean apparent diffusion coefficient was significantly higher in HPV− than HPV+ primary tumours. Other sequences need further investigation. Fourteen studies used MRI to predict HPV status using clinical, radiological, and radiomics features. The reported areas under the curve (AUC) values ranged between 0.697 and 0.944. MRI can potentially be used to find differences between HPV+ and HPV− OPSCC patients and predict HPV status with reasonable accuracy. Larger studies with external model validation using independent datasets are needed before clinical implementation.

وصف الملف: application/pdf

العلاقة: https://dspace.library.uu.nl/handle/1874/453734Test

الإتاحة: https://dspace.library.uu.nl/handle/1874/453734Test

المؤلفون: Shen, Colette, Abdou, Yara, Chen, Linda, Tan, Xianming, Gupta, Gaorav, Lynce, Filipa, Lobbous, Mina, Stringer-Reasor, Erica, Anders, Carey

المصدر: Neuro-Oncology Advances ; volume 5, issue Supplement_3, page iii39-iii39 ; ISSN 2632-2498

مصطلحات موضوعية: Surgery, Oncology, Neurology (clinical)

الوصف: BACKGROUND Despite progress in the treatment of brain metastasis (BrM) for HER2+ breast cancer (BC), outcomes for patients with HER2-negative BC BrM remain poor. Current standard of care consists of surgery and/or radiotherapy followed by systemic therapy. Preclinical studies show inhibitors of poly(ADP-ribose) polymerase (PARP) are effective together with radiotherapy as DNA damage response inhibitors. Triple-negative BC (TNBC) has higher rates of homologous recombination deficiency compared to other BC subtypes, and together with HER2-negative, BRCA-mutated BC would be particularly sensitive to PARP inhibition. PARP inhibition with immunotherapy has demonstrated promising efficacy in patients with germline BRCA-mutant and metastatic TNBC in clinical trials (MEDIOLA, TOPACIO). In addition, immunotherapy with stereotactic radiosurgery (SRS) is associated with favorable outcomes in patients with BrM. We hypothesize that this biologically-driven combination will enhance local control of SRS-treated BrM through synergy with PARP inhibition, while controlling micrometastatic disease in the brain and extracranial sites by potentiating the immune response. METHODS We are conducting a multi-institution, Phase I/II trial of SRS plus olaparib, followed by durvalumab (with physician’s choice systemic therapy), for patients with TNBC (any BRCA status) or HER2-negative with BRCA-mutated (germline or somatic) BC BrM [NCT04711824]. The primary objectives are to evaluate safety and tolerability (Phase I) and intracranial disease control at 6 months (Phase II). Secondary objectives include assessing intracranial and global progression-free survival, overall survival, and intracranial/extracranial response rate. Exploratory objectives will assess potential biomarkers of treatment response, including changes in circulating tumor cells/DNA in blood and cerebrospinal fluid, germline and tumor mutations in DNA repair pathway genes, and PD-L1 expression, as well as quality of life and patient-reported outcomes. A surgical ...

الإتاحة: https://doi.org/10.1093/noajnl/vdad070.151Test
https://academic.oup.com/noa/article-pdf/5/Supplement_3/iii39/51037592/vdad070.151.pdfTest

المؤلفون: Sandhu, Sonia K, Chen, Linda

المصدر: Open Forum Infectious Diseases ; volume 10, issue Supplement_2 ; ISSN 2328-8957

مصطلحات موضوعية: Infectious Diseases, Oncology

الوصف: Background The COVID-19 pandemic has resulted in 600 million cases and 6 million deaths globally since December 2019. Medical Information (MI) departments are critical during public health emergencies, providing factual, balanced and non-promotional information to healthcare providers (HCPs) and patients on new treatments, in compliance with industry codes of conduct. Methods Unsolicited MI requests for COVID-19 treatment from Jan 2020 to Dec 2022 were analyzed to show the customer journey and evolving needs for drug education. Data gathering and metric analysis were collected from MI databases with interaction dates, countries, contact channels, and responses. Results MI received 60,000+ unsolicited requests globally from Jan 2020 to Dec 2022, including 4,400 from patients. Pharmacists (60%) and physicians (15%) were the primary HCPs who contacted MI. Japan and US had the highest number of HCP questions. Changes in HCP questions over time reflected external events such as regulatory approvals and guideline updates, with initial questions related to medication access and clinical trials in 2020, transitioning to medication dosing and preparation in 2021, and new interests emerging in special populations including renal impairment, pediatrics, and pregnancy in 2022. These results suggest that HCPs used MI to help make clinical decisions about which medications are right for their patients. Patients preferred to contact MI by phone (71%), followed by email (25%) and digital channels (4%). Most patient questions came from US, Mexico, and India. Patients were interested in safety, drug interactions, ingredients, and mechanism of action. Nonclinical topics included drug availability, cost, clinical trial enrollment, and patient assistance programs. Increased patient questions were observed during changes in the medical landscape due to external events (label changes, data updates, and new variants). Conclusion Analyzing MI requests is a valuable tool for understanding and meeting the evolving customer needs ...

الإتاحة: https://doi.org/10.1093/ofid/ofad500.1180Test
https://academic.oup.com/ofid/article-pdf/10/Supplement_2/ofad500.1180/53754080/ofad500.1180.pdfTest

المؤلفون: Youssef, Irini, Mohamed, Nader, Kallini, Daniel, Zakeri, Kaveh, Lin, Haibo, Han, Dong, Qi, Hang, Nosov, Anton, Riaz, Nadeem, Chen, Linda, Yu, Yao, Dunn, Lara Ann, Sherman, Eric J., Wray, Rick, Schöder, Heiko, Lee, Nancy Y.

المساهمون: National Cancer Institute, National Institutes of Health

المصدر: International Journal of Radiation Oncology*Biology*Physics ; ISSN 0360-3016

مصطلحات موضوعية: Cancer Research, Radiology, Nuclear Medicine and imaging, Oncology, Radiation

الإتاحة: https://doi.org/10.1016/j.ijrobp.2024.03.011Test
https://api.elsevier.com/content/article/PII:S0360301624004280?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0360301624004280?httpAccept=text/plainTest

المؤلفون: Aristophanous, Michalis, Aliotta, Eric, Lichtenwalner, Phillip, Abraham, Shira, Nehmeh, Mohammad, Caringi, Amanda, Zhang, Peng, Hu, Yu-Chi, Zhang, Pengpeng, Cervino, Laura, Gelblum, Daphna, McBride, Sean, Riaz, Nadeem, Chen, Linda, Yu, Yao, Zakeri, Kaveh, Lee, Nancy

المساهمون: NIH, EMD Serono, National Cancer Institute

المصدر: International Journal of Radiation Oncology*Biology*Physics ; ISSN 0360-3016

مصطلحات موضوعية: Cancer Research, Radiology, Nuclear Medicine and imaging, Oncology, Radiation

الإتاحة: https://doi.org/10.1016/j.ijrobp.2024.02.016Test
https://api.elsevier.com/content/article/PII:S0360301624003262?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0360301624003262?httpAccept=text/plainTest

المؤلفون: Elshaboury, Ramy H, Adamsick, Meagan L, Huang, Joanne, Winkler, Marisa, Ghebremichael, Musie, Cheung, Fiona, Polsonetti, Bryan, Mozaffari, Essy, Chen, Linda, Juelg, Boris, Hohmann, Elizabeth

المصدر: Open Forum Infectious Diseases ; volume 9, issue Supplement_2 ; ISSN 2328-8957

مصطلحات موضوعية: Infectious Diseases, Oncology

الوصف: Background Remdesivir (RDV) has been a mainstay of COVID-19 therapy for hospitalized patients. Impact of RDV timing in relationship to symptom-onset in hospitalized patients remains unclear, though early treatment is theorized to improve antiviral activity and clinical outcomes. Methods This was a single-center retrospective study of adult patients hospitalized for severe COVID-19 treated with RDV. Patient charts were reviewed by 2 independent investigators to determine disease course and outcomes. Patients were stratified based on time from symptom-onset to RDV (short: ≤7 vs. long: >7 days). The primary outcome was time to clinical recovery within 28 days. Secondary outcomes were proportion of patients recovered and proportion discharged from the hospital within 10, 14, and 28 days; and mortality within 28 days. Time to recovery was analyzed using the Kaplan-Meier method and the significance was tested by log rank tests. Cox’s proportional hazards models were used to estimate hazard ratios (HR). Fisher’s exact test was used to compare recovery rates between groups. Results Overall, 405 patient charts were reviewed, and 337 met the inclusion criteria. On the first day of RDV, 178 (53%) of patients had symptoms for <7 days, while 159 (47%) of patients had symptoms for >7 days. Patients in the short symptom duration group were slightly older (66.5 vs. 59 years, p=0.004) and had more co-morbidities. Median time to recovery was 7 (95% CI 5-9) in the short- vs. 5 (95% CI 4-6) days in the long-symptom duration groups, respectively, p=0.066. By day 10, 111 (62%) vs. 116 (73%) patients met the clinical recovery definition (p=0.048), and 113 (63%) vs. 119 (75%) patients were discharged from the hospital (p=0.026) in the short- vs. long-symptom duration groups, respectively. In the Cox’s proportional hazards model, age, disease severity, and co-morbidities (kidney, liver, chronic respiratory diseases, and type II diabetes mellitus) were associated with longer recovery times. Conclusion In ...

الإتاحة: https://doi.org/10.1093/ofid/ofac492.993Test
https://academic.oup.com/ofid/article-pdf/9/Supplement_2/ofac492.993/47892525/ofac492.993.pdfTest

المؤلفون: Hesse, Jennifer, Chen, Linda, Yu, Yao, Kang, Jung Julie, Riaz, Nadeem, Tsai, C. Jillian, McBride, Sean M., Gelblum, Daphna, Zakeri, Kaveh, Lee, Nancy Y.

المساهمون: National Institutes of Health

المصدر: Advances in Radiation Oncology ; volume 7, issue 3, page 100917 ; ISSN 2452-1094

مصطلحات موضوعية: Radiology, Nuclear Medicine and imaging, Oncology

الإتاحة: https://doi.org/10.1016/j.adro.2022.100917Test
https://api.elsevier.com/content/article/PII:S2452109422000240?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2452109422000240?httpAccept=text/plainTest

المؤلفون: Mendoza, Maria A, Coro, Ana, Natori, Yoichiro, Anjan, Shweta, Guerra, Giselle, Mattiazzi, Adela, Chen, Linda, Morsi, Mahmoud, Figueiro, Jose, Raveh, Yehuda, Simkins, Jacques

المصدر: Open Forum Infectious Diseases ; volume 8, issue Supplement_1, page S756-S756 ; ISSN 2328-8957

مصطلحات موضوعية: Infectious Diseases, Oncology

الوصف: Background Outcomes of COVID-19 have been reported in deceased donor kidney transplant (DDKT) recipients. However, data is limited in patients that underwent recent DDKT. Methods This single-center retrospective study evaluated the differences in demographics and post-transplant outcomes between those who tested positive and negative for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by polymerase chain reaction, after undergoing recent DDKT. The treatments and outcomes for the SARS-CoV-2-positive patients were assessed. Patients who underwent DDKT from 3/2020 to 8/2020 were included and followed until 9/2020. Results 201 DDKT recipients were analyzed [14(7%) SARS-CoV-2-positive and 187(93%) negative]. There was no difference in delayed graft function and biopsy-proven rejection between both groups. The patient survival at the end of the study follow-up was lower among SARS-CoV-2-positive patients (Table 1). The median time from DDKT to COVID-19 diagnosis was 45 (range: 8-90) days; 5(36%) patients required intensive care unit and 4(29%) required mechanical ventilation; steroids were used in all the patients, therapeutic plasma exchange (TPE) and convalescent plasma (CP) in 7(50%) patients each, remdesivir in 6(43%) and tocilizumab in 1(7%); 9(64%) patients recovered, 3(21%) died and two were still requiring mechanical ventilation at the end of the follow-up. Conclusion Our cohort demonstrated a lower survival rate among SARS-CoV-2-positive patients, which highlights the vulnerability of the transplant population. Transplant patients must comply with the CDC recommendations to prevent COVID-19. Disclosures All Authors: No reported disclosures

الإتاحة: https://doi.org/10.1093/ofid/ofab466.1528Test
https://academic.oup.com/ofid/article-pdf/8/Supplement_1/S756/41521753/ofab466.1528.pdfTest

المؤلفون: Yu, Yao, Schöder, Heiko, Zakeri, Kaveh, Chen, Linda, Kang, Jung Julie, McBride, Sean Matthew, Tsai, C. Jillian, Gelblum, Daphna Y., Boyle, Jay O., Cracchiolo, Jennifer R., Cohen, Marc A., Singh, Bhuvanesh, Ganly, Ian, Patel, Snehal G., Michel, Loren S., Dunn, Lara, Sherman, Eric J., Pfister, David G., Wong, Richard J., Riaz, Nadeem, Lee, Nancy Y.

المساهمون: National Institutes of Health, National Cancer Institute, Memorial Sloan-Kettering Cancer Center

المصدر: Oral Oncology ; volume 141, page 106400 ; ISSN 1368-8375

مصطلحات موضوعية: Cancer Research, Oncology, Oral Surgery

الإتاحة: https://doi.org/10.1016/j.oraloncology.2023.106400Test
https://api.elsevier.com/content/article/PII:S1368837523000969?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1368837523000969?httpAccept=text/plainTest

المؤلفون: Cheng, Zhi, Rosati, Lauren M., Chen, Linda, Mian, Omar Y., Cao, Yilin, Villafania, Marta, Nakatsugawa, Minoru, Moore, Joseph A., Robertson, Scott P., Jackson, Juan, Hacker-Prietz, Amy, He, Jin, Wolfgang, Christopher L., Weiss, Matthew J., Herman, Joseph M., Narang, Amol K., McNutt, Todd R.

المساهمون: Commonwealth Foundation, Elekta, Philips, Toshiba Medical Systems Corporation

المصدر: Advances in Radiation Oncology ; volume 3, issue 4, page 601-610 ; ISSN 2452-1094

مصطلحات موضوعية: Radiology, Nuclear Medicine and imaging, Oncology

الإتاحة: https://doi.org/10.1016/j.adro.2018.07.002Test
https://api.elsevier.com/content/article/PII:S2452109418301234?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2452109418301234?httpAccept=text/plainTest